FY2029 Earnings Forecast for DNLI Issued By B. Riley

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at B. Riley issued their FY2029 earnings per share (EPS) estimates for shares of Denali Therapeutics in a note issued to investors on Wednesday, March 5th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of $0.87 for the year. B. Riley has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

A number of other analysts have also recently commented on the stock. Morgan Stanley started coverage on shares of Denali Therapeutics in a research report on Friday. They set an "overweight" rating and a $33.00 price target on the stock. Stifel Nicolaus raised Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target on the stock. Finally, HC Wainwright lifted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.20.

Remove Ads

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI traded down $1.74 during trading on Thursday, reaching $14.95. The stock had a trading volume of 1,740,811 shares, compared to its average volume of 1,007,483. Denali Therapeutics has a 52 week low of $14.01 and a 52 week high of $33.33. The firm's fifty day moving average is $20.80 and its 200 day moving average is $24.30. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -5.42 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.08.

Insider Activity

In related news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Ryan J. Watts sold 29,266 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares of the company's stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock worth $973,442 over the last 90 days. 7.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Hedge funds have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after purchasing an additional 1,516 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Denali Therapeutics in the 4th quarter worth about $62,000. Point72 Hong Kong Ltd bought a new stake in Denali Therapeutics in the 4th quarter worth approximately $65,000. Quest Partners LLC purchased a new position in shares of Denali Therapeutics during the third quarter worth approximately $73,000. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.